Literature DB >> 2535930

Implications of accurate pathologic margins in the treatment of primary breast cancer.

T G Frazier1, R W Wong, D Rose.   

Abstract

Eighty-seven patients who underwent mastectomy or reexcision following a previous segmental resection with pathologic margins evaluated at that time were restudied following their definitive therapy. Of these, 40 (46.0%) had involved margins, 28 (32.2%) had close margins, and 19 (21.8%) had clear margins. Residual tumor was subsequently found in 21 (52.5%) of 40, nine (32.1%) of 28, and five (26.3%) of 19, respectively. Analysis of specimens for quadrant of residual tumor showed 27 (31.0%) of 87 patients in the same quadrant, and 11 (14.7%) of 75 present in a different quadrant. The assessment of microscopic margins may be misleading since 29.8% (14/47) of patients with clear or close margins subsequently had residual tumor, and 47.5% (19/40) of those with involved margins had no residual tumor found. Further studies are essential to define the optimum guidelines for tumor excision at the time of segmental resection.

Entities:  

Mesh:

Year:  1989        PMID: 2535930     DOI: 10.1001/archsurg.1989.01410010043009

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  10 in total

1.  Pathologic Assessment of Surgical Margins on Frozen and Permanent Sections in Breast Conserving Surgery.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

Review 2.  Risk factors and management of local recurrence following breast conservation surgery.

Authors:  R T Osteen
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

3.  Frozen-section-guided breast-conserving surgery: implications of diagnosis by frozen section as a guide to determining the extent of resection.

Authors:  T Ikeda; K Enomoto; K Wada; K Takeshima; K Yoneyama; J Furukawa; Y Watanabe; M Mukai; M Kitajima
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

4.  The optimal extent of resection for patients with stages I or II breast cancer treated with conservative surgery and radiotherapy.

Authors:  F A Vicini; T J Eberlein; J L Connolly; A Recht; A Abner; S J Schnitt; W Silen; J R Harris
Journal:  Ann Surg       Date:  1991-09       Impact factor: 12.969

5.  A comparison of large block macrosectioning and conventional techniques in breast pathology.

Authors:  P A Jackson; W Merchant; C J McCormick; M G Cook
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

6.  A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072.

Authors:  Rache M Simmons; Karla V Ballman; Charles Cox; Ned Carp; Jennifer Sabol; Rosa F Hwang; Deanna Attai; Michael Sabel; David Nathanson; Andrew Kenler; Linsey Gold; Cary Kaufman; Linda Han; Aaron Bleznak; J Stanley Smith; Dennis Holmes; Bruno Fornage; Carisa Le-Petross; Syed Hoda; Linda McCall; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2016-05-24       Impact factor: 5.344

Review 7.  Current status of photodynamic therapy in oncology.

Authors:  R van Hillegersberg; W J Kort; J H Wilson
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

8.  Biological markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size.

Authors:  E R Sauter; H Ehya; J Babb; E Diamandis; M Daly; A Klein-Szanto; E Sigurdson; J Hoffman; J Malick; P F Engstrom
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

9.  Adjuvant intraoperative photodynamic therapy diminishes the rate of local recurrence in a rat mammary tumour model.

Authors:  R van Hillegersberg; J M Hekking-Weijma; J H Wilson; A Edixhoven-Bosdijk; W J Kort
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

10.  In vitro irradiation of basement membrane enhances the invasiveness of breast cancer cells.

Authors:  B Paquette; C Baptiste; H Therriault; G Arguin; B Plouffe; R Lemay
Journal:  Br J Cancer       Date:  2007-11-06       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.